Related Experiment Video
Updated: Jul 1, 2025
Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
Published on: July 22, 2019
GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy
M Caforio1, S Iacovelli2, C Quintarelli1
1U.O. Cellular and Genetic Therapy of Hematological Diseases, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Background:
CRISPR/Cas9 system to treat human-related diseases has achieved significant results and, even if its potential application in cancer research is improving, the application of this approach in clinical practice is still a nascent technology.
Main Body:
CRISPR/Cas9 technology is not yet used as a single therapy to treat tumors but it can be combined with traditional treatment strategies to provide personalized gene therapy for patients. The combination with chemotherapy, radiation and immunotherapy has been proven to be a powerful means of screening, identifying, validating and correcting tumor targets. Recently, CRISPR/Cas9 technology and CAR T-cell therapies have been integrated to open novel opportunities for the production of more efficient CAR T-cells for all patients. GMP-compatible equipment and reagents are already available for several clinical-grade systems at present, creating the basis and framework for the accelerated development of novel treatment methods.
Conclusion:
Here we will provide a comprehensive collection of the actual GMP-grade CRISPR/Cas9-mediated approaches used to support cancer therapy highlighting how this technology is opening new opportunities for treating tumors.
Insights
The CRISPR/Cas9 gene editing system shows promise for cancer therapy, particularly when combined with existing treatments. This technology is advancing towards clinical applications for personalized cancer gene therapy.
Area of Science:
- Genomic Medicine
- Gene Editing Technologies
- Oncology
Background:
- CRISPR/Cas9 technology has shown significant results in treating human diseases.
- Its application in cancer research is growing, but clinical use is still emerging.
- CRISPR/Cas9 is not yet a standalone cancer therapy but enhances existing strategies.
Purpose of the Study:
- To provide a comprehensive overview of GMP-grade CRISPR/Cas9 approaches for cancer therapy.
- To highlight the emerging opportunities for tumor treatment using this technology.
Main Methods:
- CRISPR/Cas9 is combined with chemotherapy, radiation, and immunotherapy for personalized gene therapy.
- Integration with CAR T-cell therapy enhances efficiency and broadens patient applicability.
- Availability of GMP-compatible equipment and reagents facilitates clinical development.
Main Results:
- CRISPR/Cas9-mediated strategies are powerful for targeting tumors.
- Combination therapies improve screening, identification, validation, and correction of tumor targets.
- Novel opportunities arise from integrating CRISPR/Cas9 with CAR T-cell therapies.
Conclusions:
- GMP-grade CRISPR/Cas9 approaches are crucial for advancing cancer therapy.
- This technology is opening new avenues for effective tumor treatment.
- The integration of CRISPR/Cas9 into clinical practice is accelerating.
Related Concept Videos
01:59CRISPR
02:53CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
02:31Homologous Recombination